The global Hepatitis C Drug market will derive growth impetus from the high prevalence of hepatitis C across the world. According to a report published by Fortune Business Insights, titled “Hepatitis C Drug: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 7,866.6 Mn in 2018. Fortune Business Insights states that the market is projected to reach US$ 7,351.7 Mn by 2026, exhibiting a CAGR of -0.9% in the forecast period.
Hepatitis C is a viral infection that causes severe damage such as inflammation of the liver and can spread through contaminated blood. The advanced stages of hepatitis C can also lead to liver damage, thereby creating severe health risks. The severity of hepatitis C has created a huge emphasis on the research and development of drugs associated with the treatment of this disease. Several new drugs have been launched in recent times, due to the high prevalence of hepatitis C across the world. Hepatitis C requires oral injections and dosages on a weekly basis, and it also has several side effects that can also lead to permanent damage.
Top players in the global Type 1 Hepatitis C Drug Market include:
- AbbVie Inc.
- Gilead Sciences, Inc.
- Bristol-Myers Squibb Company
- Janssen Pharmaceuticals, Inc.
- Merck Sharp & Dohme Corp.
- Hoffmann-La Roche Ltd
- Vertex Pharmaceuticals Incorporated
Huge Hepatitis C Patient Pool Will Offer Growth Opportunities for the Market in North America
The high prevalence of hepatitis C has created a need for efficient drugs at low cost. Fortune Business Insights has identified increasing hepatitis C incidence as a primary growth driver. The increased adoption of Hepatitis C Drug will favor the growth of the market in North America. Fortune Business Insights has predicted that the Hepatitis C Drug market in North America will witness considerable growth, driven by the high demand for Hepatitis C Drug.
Furthermore, recent drug advancements will fuel the demand for related drugs, subsequently aiding market growth. Fortune Business Insights states that the Hepatitis C Drug market in North America was valued at US$ 3,736.6 Mn in 2018.
By Product Type
- NS5A Inhibitor (Protease Inhibitors)
- Fixed-dose Combination
By Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America (U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)
Fortune Business Insights profiles a few of the prominent companies that are operating in the global market. Some of the leading companies that have established standout market positions are AbbVie Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., F. Hoffmann-La Roche Ltd, and Vertex Pharmaceuticals Incorporated.
More Trending Topics From Fortune Business [email protected]